PhD, Molecular Pathogenesis and Molecular Medicine, University of Chicago
BS, Bioengineering, University of Illinois Urbana-Champaign
HIV pathogenesis, broadly neutralizing antibodies, passive immunization, and COVID-19
Jeffrey R. Schneider, PhD’s lab focuses on HIV antibody distribution. He has helped develop a platform to track intravenous injected fluorophore conjugated IgG in plasma, tissue, and weck-cel fluid. This methodology has led to a grant to study how the timing of antibody injection affects distal site accumulation of virus following challenge. Through a better understanding of how antibodies get to and fortify mucosal surfaces from incoming pathogens, this research has the potential to elucidate novel HIV prevention strategies with the ultimate goal of blocking initial HIV transmission. This work will help inform future passive immunization studies, such as the AMP (Antibody Mediated Prevention) trial which is currently underway and administering anti-HIV antibodies to at-risk individuals around the world. As the SARS-CoV-2 pandemic emerged, Schneider has adapted his work with HIV antibodies to better understand the neutralizing antibody response in COVID-19 patients.